Payload Information
General Information of This Payload
| Payload ID | PAY0RQAUL |
|||||
|---|---|---|---|---|---|---|
| Name | Triamcinolone acetonide |
|||||
| Synonyms |
Triamcinolone acetonide
Click to Show/Hide
|
|||||
| Target | Glucocorticoid receptor (GR) | |||||
| Formula | C24H31FO6 |
|||||
| Isosmiles | C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(C=C[C@@]43C)=O)[C@@H]1C[C@@H]5[C@@]2(C(CO)=O)OC(C)(C)O5 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C24H31FO6/c1-20(2)30-19-10-16-15-6-5-13-9-14(27)7-8-21(13,3)23(15,25)17(28)11-22(16,4)24(19,31-20)18(29)12-26/h7-9,15-17,19,26,28H,5-6,10-12H2,1-4H3/t15-,16-,17-,19+,21-,22-,23-,24+/m0/s1
|
|||||
| InChIKey |
YNDXUCZADRHECN-JNQJZLCISA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
434.504 |
Polar area |
93.06 |
||
Complexity |
896.999098 |
xlogp Value |
2.4188 |
|||
Heavy Count |
31 |
Rot Bonds |
2 |
|||
Hbond acc |
6 |
Hbond Donor |
2 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cell-based Percent Inhibition (%) | -10.99 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -3.3 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | -5.82 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 0.44 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 0.44 | % |
Vero C1008 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 0.96 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 115.53 | % |
CHO cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 128.12 | % |
CHO cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 14.59 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 16.43 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 25 | % |
NIH3T3 cells
|
Normal
|
||
| Cell-based Percent Inhibition (%) | 28.78 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 3.43 | % |
Caco-2 cells
|
Colon adenocarcinoma
|
||
| Cell-based Percent Inhibition (%) | 3.69 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 32 | % | Undisclosed | Undisclosed | Undisclosed | |
| Cell-based Percent Inhibition (%) | 7.65 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >133000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 179 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >19952.62 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Activity Concentration (AC50) | 20 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
Vero C1008 cells
|
Normal
|
||
| Half Maximal Activity Concentration (AC50) | 23000.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2500 | nM |
NIH3T3 cells
|
Normal
|
||
| Half Maximal Activity Concentration (AC50) | 3.1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 3.9 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | >30000 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 4.414 | nM |
HeLa S3 cells
|
Endocervical adenocarcinoma
|
||
| Half Maximal Activity Concentration (AC50) | 44668.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Activity Concentration (AC50) | 44.67 | uM | Undisclosed | Undisclosed | Undisclosed |
Each Antibody-drug Conjugate Related to This Payload